OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Cancer is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Subscription & copyright page	334
Platelets: tailoring metastasis treatment	213
Engineering growth factor ligands and receptors for therapeutic innovation	213
Revumenib: a new era in acute leukemia treatment	196
Spliced to kill: RNA mis-splicing derived cancer neoantigens	192
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	175
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	171
FBXW10: a male-biased E3 ligase in liver cancer	163
Tumor-resident microbes: the new kids on the microenvironment block	152
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	152
Advisory Board and Contents	151
Navigating life as an early career researcher	151
Subscription & copyright page	148
Subscription and copyright page	145
Accessing the vasculature in cancer: revising an old hallmark	134
Leveraging circulating microbial DNA for early cancer detection	133
Onco-condensates: formation, multi-component organization, and biological functions	130
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	124
Radiotherapy and immunotherapy: open questions and future strategies	124
Engine shutdown: migrastatic strategies and prevention of metastases	123
Subscription & copyright page	102
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	89
Diet, nutrient supply, and tumor immune responses	87
GOT2 consider the tumor microenvironment	87
Gut microbiota – a double-edged sword in cancer immunotherapy	86

cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	82
Pannexin biology and emerging linkages to cancer	82
Regulation of metastatic organotropism	76
Oncogenic competence: balancing mutations, cellular state, and microenvironment	76
Benefits and opportunities of the transgenic Oncopig cancer model	76
Crosstalk of T cells within the ovarian cancer microenvironment	74
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	73
Tumor immunology CRISPR screening: present, past, and future	70
Chromatin as an old and new anticancer target	70
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	67
Chromosomal instability and aneuploidy as causes of cancer drug resistance	67
Recent developments in myeloid immune modulation in cancer therapy	66
Cell death, therapeutics, and the immune response in cancer	63
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	60
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	59
Subscription & copyright page	58
Advisory Board and Contents	58
Advisory Board and Contents	58
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	57
Insights on ErbB glycosylation – contributions to precision oncology	56
Subscription & copyright page	55
Advisory Board and Contents	55
Scaling data toward pan-cancer foundation models	52
β-Galactosylceramidase in cancer: friend or foe?	52
Genetic immune escape in cancer: timing and implications for treatment	52
Organellar pH as an emerging vulnerability to exploit in cancer	51